- Trials with a EudraCT protocol (12)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
12 result(s) found for: Respect for persons.
Displaying page 1 of 1.
EudraCT Number: 2006-005637-37 | Sponsor Protocol Number: ASF-1057-206 | Start Date*: 2007-02-28 |
Sponsor Name:Astion Danmark A/S | ||
Full Title: Comparative, placebo controlled, double-blind efficacy and safety study in patients with seborrhoeic dermatitis comparing a topical cream containing 2% Nicotinamide combined with either 0%, 0.5% or... | ||
Medical condition: Seborrhoeic Dermatitis. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-002842-37 | Sponsor Protocol Number: FG-56-02 | Start Date*: 2004-11-23 | |||||||||||
Sponsor Name:Fujisawa GmbH | |||||||||||||
Full Title: A randomised, double-blind, vehicle-controlled, parallel group, multicentre, proof of concept, phase II clinical study to investigate the efficacy and safety of 1 % FR260500 gel in patients with fa... | |||||||||||||
Medical condition: Mild to moderate facial acne vulgaris. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021356-26 | Sponsor Protocol Number: 111679 | Start Date*: 2011-01-03 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
Full Title: A Phase IIb, randomized, observer-blind, placebo controlled, multicenter primary/booster therapeutic vaccination study to determine efficacy and safety of F4co/ AS01B vaccine, administered intramus... | |||||||||||||
Medical condition: ART-naïve HIV-infected adults (ART: anti-retroviral therapy) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001386-16 | Sponsor Protocol Number: TUD-TEMACA-069 | Start Date*: 2019-07-16 |
Sponsor Name:Technische Universität Dresden | ||
Full Title: Investigation of the efficacy of acamprosate and calcium in comparison to placebo as validation of a behavioural test for alcohol dependence (TEMACA) | ||
Medical condition: persons with disturbance in alcohol use according DSM5 which do not want to change their alcohol consumption | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2007-004635-29 | Sponsor Protocol Number: ASF-1096-301 | Start Date*: 2007-11-07 |
Sponsor Name:Astion Pharma A/S | ||
Full Title: Randomised, placebo controlled, international multi-centre, double blind, dose confirmation study testing the safety and efficacy of ASF-1096 cream 0.25%, 0.5% and 1% and placebo applied twice dail... | ||
Medical condition: Patients with Discoid Lupus Erythematosus (DLE) or Subacute Cutaneous Lupus Erythematosus (SCLE) symptoms of the skin can be included in this study. Those patients who have a diagnosis of Systemic ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) DK (Completed) ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004499-36 | Sponsor Protocol Number: VIHOSB | Start Date*: 2019-08-07 |
Sponsor Name:Consorci Mar Parc de Salut de Barcelona | ||
Full Title: Study to assess bone health with bone mineral density, bone microarchitecture and bone tissue quality after switching from a TDF regimen to Bictegravir-TAF-FTC | ||
Medical condition: Bone health (bone mineral density, microarchitecture and bone quality) in HIV individuals under antiretroviral treatment with tenofovir disoproxil fumarate (TDF) that change treatment to bictegravi... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-023978-39 | Sponsor Protocol Number: 20080261 | Start Date*: 2011-05-23 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Trial of AMG 479 or Placebo in Combination with Gemcitabine as First-line Therapy for Locally Advanced Unresectable Adenocarcin... | |||||||||||||
Medical condition: Locally advanced adenocarcinoma of the pancreas | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) PT (Prematurely Ended) BE (Prematurely Ended) AT (Prematurely Ended) CZ (Completed) PL (Prematurely Ended) SE (Prematurely Ended) HU (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004354-15 | Sponsor Protocol Number: DANPAPP | Start Date*: 2017-12-13 | ||||||||||||||||
Sponsor Name: Rigshospitalet | ||||||||||||||||||
Full Title: Prevalence, pattern and disease course of arthritis and enthesitis in patients with psoriasis, and the effect of apremilast in subclinical US-defined psoriatic arthritis - A population-based study ... | ||||||||||||||||||
Medical condition: Psoriasis and psoriatic arthritis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-005476-27 | Sponsor Protocol Number: CACZ885G2305 | Start Date*: 2009-05-14 | |||||||||||
Sponsor Name:Novartis Farmacéutica S.A. | |||||||||||||
Full Title: Estudio randomizado, doble ciego, controlado con placebo, a dosis única para evaluar la eficacia inicial de canakinumab (ACZ885) respecto a los Criterios ACR 30 Pediátricos Adaptados en pacientes c... | |||||||||||||
Medical condition: Artritis idiopática juvenil sistémica y manifestaciones sistémicas activas. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) NO (Ongoing) FR (Completed) HU (Completed) DE (Completed) BE (Completed) SE (Completed) IT (Completed) GB (Completed) DK (Completed) GR (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006439-12 | Sponsor Protocol Number: INSIGHT001:STARTDAIDSID#10619 | Start Date*: 2009-05-25 |
Sponsor Name:Regents of the University of Minnesota | ||
Full Title: Strategic Timing of AntiRetroviral Treatment(START) | ||
Medical condition: HIV Infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) FI (Completed) ES (Completed) DE (Completed) GB (GB - no longer in EU/EEA) GR (Completed) IT (Completed) SE (Completed) PT (Completed) IE (Completed) EE (Completed) NO (Completed) AT (Completed) CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-012072-28 | Sponsor Protocol Number: MO22468 | Start Date*: 2009-11-23 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: Estudio randomizado en fase IIIb de MabThera® (rituximab) agregado a quimioterápia, bendamustina o clorambucilo, en pacientes con leucemia linfática crónica. A randomized Phase IIIb study of MabTh... | |||||||||||||
Medical condition: Pacientes con leucemia linfática crónica (LLC) en primera linea o segunda línea (máximo de una línea de tratamiento previa) con necesidad de tratamiento. (En España, solo se incluirán pacientes en ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) SE (Completed) FR (Completed) FI (Completed) PT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-007198-21 | Sponsor Protocol Number: H9X-MC-GBCF | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Eli Lilly and Company - Indianapolis | |||||||||||||
Full Title: A Phase 2/3, Placebo-Controlled, Efficacy and Safety Study of Once-Weekly, Subcutaneous LY2189265 Compared to Sitagliptin in Patients with Type 2 Diabetes Mellitus on Metformin | |||||||||||||
Medical condition: Type 2 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
